SAB BIO Q3 2026 Earnings Call - SAB BIOTHERAPEUTICS INC

Financial Performance:

• Ended Q3 2026 with $205 million in cash, cash equivalents, and investment securities, projected to fund operations through 2028.
• Received $13.4 million in gross proceeds from warrant exercises in Q3 2026.
• Research & Development (R&D) expenses were $18.1 million (vs. $9.0 million in Q3 2025), driven by clinical trial costs for the Safeguard study and increased headcount.
• General & Administrative (G&A) expenses were $7.8 million (vs. $3.7 million in Q3 2025), driven by personnel costs and stock-based compensation.
• Net loss for Q3 2026 was $22.3 million, compared to a net income of $45.4 million in Q3 2025; the variance primarily reflects a $3.6 million change in the fair value of warrant liabilities recognized in 2025.
• Non-cash stock-based compensation totaled $7.5 million for Q3 2026 ($3.9M in R&D, $3.6M in G&A).

Guidance and Future Outlook:

• Reaffirmed guidance to complete enrollment of the Phase 2b Safeguard study in Q4 2026, with top-line data expected in the second half of 2027.
• The investigator-led Phase 3 PRIZE study is expected to dose its first patient in Q4 2026.
• Future outlook focuses on advancing SAB142 toward commercial readiness and preparing for potential label expansion for patients up to two years post-diagnosis.
• Management expresses confidence in SAB142's potential to redefine treatment for Stage 3 Type 1 Diabetes (T1D).

Business Segments and Product Lines:

• Core focus remains on SAB142, a fully human antithymocyte immunoglobulin developed on the proprietary TC bovine platform to preserve insulin-producing beta cells.
• Safeguard Study: Adult and adolescent cohorts are fully enrolled and closed for screening; the study approved a step-down to pediatric patients (ages 5–11) in September to accelerate enrollment.
• PRIZE Study: Designed to evaluate efficacy in patients up to two years post-diagnosis; involves seven clinical sites across the US, Europe, and the UK, co-funded by SAB Bio and supported by a grant from Breakthrough T1D.
• Regulatory Milestone: FDA granted Fast-Track designation for SAB142 for new-onset Stage 3 T1D in October, enabling frequent FDA interactions and eligibility for priority review.

Market and Competitive Landscape:

• Market sentiment is positive, with management noting that the recent approval of T-field (Teplizumab) validates the treatment paradigm for beta-cell preservation and establishes a pattern for prescribing.
• SAB142 differentiates from T-field by offering a disease-modifying therapy with a lower dosing frequency (fewer days of dosing) and the potential for lifetime redosing due to low immunogenicity (fully human antibody).
• High physician and patient interest exists for the PRIZE study, addressing pent-up demand among patients excluded from current therapies due to strict time-from-diagnosis windows (T-field: 8 weeks, Safeguard: 100 days).

Risks and Challenges:

• Clinical trial execution risks remain, though the Data Monitoring Committee (DMC) has confirmed safety consistency across age groups without new safety signals.
• The PRIZE study is investigator-led; while supported by a grant, management has not yet guided on specific data release timing or label expansion confirmation pending study outcomes.
• No guarantee of FDA approval exists despite Fast-Track designation, and results depend on meeting primary endpoints for beta-cell preservation (C-peptide).

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing "strong momentum," "exemplary" clinical team performance, and "serious aura" surrounding the Fast-Track designation.
• Management highlighted the strategic advantage of the TC bovine platform in generating fully human antibodies without human donors.
• Leadership expressed gratitude to the diabetes community and emphasized the long-term potential to change the course of the disease.

Analyst Questions and Answers:

• C-peptide vs. A1C: C-peptide (beta-cell preservation) is the primary endpoint; statistically significant results here are required for accelerated approval. HbA1c and continuous glucose monitoring data will also be reported.
• Redosing and Immunogenicity: SAB142 is expected to show low immunogenicity allowing for lifetime redosing to maintain beta-cell function, a key differentiator from competitors.
• PRIZE Study Cohorts: The PRIZE study includes three cohorts based on time from diagnosis (0–100 days, 100 days–1 year, 1–2 years) to prove efficacy across the window where patients have adequate residual beta cells.
• Safety Data: The DMC approved pediatric enrollment in Safeguard after reviewing cumulative unblinded safety data, confirming consistent safety profiles across all age groups.
• Previous Phase 1 Data: Data on the four "super responders" from the Phase 1 study has not been updated beyond the initial 120-day visit; no follow-up data is currently available on durability without redosing.
• Burn Rate: Expenses for the PRIZE study were already factored into the Q3 budget and guidance; no change to the expected burn rate is anticipated.

Other Key Points:

• The call coincided with Diabetes Awareness Month, highlighting the company's commitment to the T1D community.
• SAB142 is designed to treat Stage 3 T1D, aiming to preserve the pancreas at a stage where patients still have residual beta cells.
• The PRIZE study is co-funded by SAB Bio and Breakthrough T1D, with principal investigators at the University of Florida, UZ Leuven, and King's College London.